MAP3K1 and cancer: To confirm the relevance of this process to different cancer types, A2780-Rab25 cells were treated with 50 μM SB203580 or siRNAs against MAP3K1, MAPK11, PPP2R1A, and α2 integrin and seeded on CDM.